ArticleCureus2025
Correlation Between Blood Transforming Growth Factor-Beta 1 (TGF-β1) Levels and Cardiac Function Parameters Following Doxorubicin Chemotherapy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDoxorubicin is an anthracycline-based chemotherapeutic agent that is effective against various malignancies. However, it is associated with significant cardiotoxic side effects, which may lead to a reduction in ejection fraction (EF), tricuspid annular plane systolic excursion (TAPSE), early (E) to late (A) diastolic filling velocities (E/A), early mitral inflow velocity and mitral annular early diastolic velocity (E/E'), and myocardial dysfunction as measured by global longitudinal strain (GLS). Transforming growth factor-beta 1 (TGF-β1) is a proinflammatory cytokine that plays a key role in cardiac fibrotic remodeling and is suspected to contribute to the pathogenesis of doxorubicin-induced cardiotoxicity. Currently, human studies investigating the association between TGF-β1 levels and cardiac function deterioration due to doxorubicin remain limited. The objective of this study is to assess the correlation between serum TGF-β1 levels and EF, E/A, E/E', TAPSE, and GLS in cancer patients 3-12 months after completing full-course doxorubicin chemotherapy, as cardiotoxicity often occurs less than 12 months after chemotherapy.
methodsThis research employed a cross-sectional design. Subjects included cancer patients who completed full-course doxorubicin chemotherapy at Cipto Mangunkusumo General Hospital and Dharmais National Cancer Hospital, and who met the inclusion and exclusion criteria. Serum TGF-β1 levels were measured between the third and 12th month post-chemotherapy, concurrently with cardiac function evaluation via echocardiography to assess EF, E/A, E/E', TAPSE, and GLS. Based on the sample size calculation, the minimum number of samples needed for this study is 55 patients. Correlation analysis was performed using Pearson or Spearman tests, depending on the data distribution. Correlation analysis was considered statistically significant if the p-value was less than 0.05.
resultA total of 56 patients were obtained for analysis. No significant correlations were found between TGF-β1 levels and EF (r = 0.308; p = 0.779), E/A (r = -0.034; p = 0.805), E/E' (r = 0.153; p = 0.259), TAPSE (r = 0.093; p = 0.494), or GLS (r = 0.052; p = 0.704) in analysis of all 56 patients. However, a significant correlation was observed between TGF-β1 and E/E' (r = 0.391; p = 0.033) in patients who received a cumulative doxorubicin dose ≥600 mg/m
conclusionThis study found no significant correlations between TGF-β1 and EF, E/A, E/E', TAPSE, or GLS in the overall cohort. In patients who had received a cumulative doxorubicin dose ≥600 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.